An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder | MicrobiomeTrials← Back to trialsNCT07812181
An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-10-01Est. Completion: 2030-10-01
Enrollment target: 20 participants Locations- Children's Hospital Los Angeles, Los Angeles, California, United States
Other microbiome trials you might be interested in
Down SyndromeRegression
Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsych…
Los Angeles, United StatesCompleted May 5, 2026